Cell-cycle inhibition by independent CDK and PCNA binding domains in p21Cip1
The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
Abstract
Mammalian cell-cycle control by antimitogenic signals involves p21Cip1/WAF1 (refs 1-4), p27Kip1 (refs 5, 6) and p57Kip2 (refs 7, 8), a family of proteins that bind to and inhibit cyclin-dependent kinases (CDKs) required for initiation of S phase. The protein p21 also binds to the DNA polymerase delta processivity factor, proliferating-cell nuclear antigen (PCNA), and inhibits in vitro PCNA-dependent DNA replication. The CDK and PCNA inhibitory activities of p21 are shown here to be functionally independent and to reside in separate protein domains. The PCNA binding and inhibitory activities, which are not observed with p27 or p57, reside in the C-terminal domain of p21, whereas the CDK inhibitory activity resides in the conserved N-terminal domains of these proteins. When separately overexpressed in mammalian cells, the CDK and PCNA inhibitory domains prevent DNA replication, demonstrating a dual function of p21 as a cell-cycle inhibitor in vivo.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“P21 functions primarily by binding to and inhibiting CDKs, and in addition, p21 halts the cell cycle by blocking PCNA, which is required for DNA replication.150, 151”
From Census and evaluation of p53 target genes (2017) · cites this paper as [150]
In the citing paper
“P21 functions primarily by binding to and inhibiting CDKs, and in addition, p21 halts the cell cycle by blocking PCNA, which is required for DNA replication.150, 151”
From Census and evaluation of p53 target genes (2017) · cites this paper as [150]
In the citing paper
“While the p21/PCNA ratio was reported to never exceed a 1:1 ratio in cells [37,38], a ratio of at least 10:1 is required to block DNA repair by nucleotide excision repair (NER) in vitro [38,39,40,41].”
From CDK-Independent and PCNA-Dependent Functions of p21 in DNA Replication (2020) · cites this paper as [38]
In the citing paper
“While the p21/PCNA ratio was reported to never exceed a 1:1 ratio in cells [37,38], a ratio of at least 10:1 is required to block DNA repair by nucleotide excision repair (NER) in vitro [38,39,40,41].”
From CDK-Independent and PCNA-Dependent Functions of p21 in DNA Replication (2020) · cites this paper as [38]
In the citing paper
“When assessing the effect of p21 on PCNA-dependent DNA synthesis in cells, several reports showed a limited or null effect of p21–PCNA interaction on DNA replication [38,45,46,47,48,49,50,51].”
From CDK-Independent and PCNA-Dependent Functions of p21 in DNA Replication (2020) · cites this paper as [38]
Citations
Cites
WAF1, a potential mediator of p53 tumor suppression
El-Deiry, W. S., Tokino, T., Velculescu, V. E., Levy, D. B., Parsons, R., Trent, J. M., Lin, D., Mercer, W. E., Kinzler, K. W., & Vogelstein, B. (1993) · Cell · doi:10.1016/0092-8674(93)90500-p · Cited by 8,321
The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases.
Wade Harper, J. (1993) · Cell · doi:10.1016/0092-8674(93)90499-g · Cited by 5,651
p21 is a universal inhibitor of cyclin kinases
Xiong, Y., Hannon, G. J., Zhang, H., Casso, D., Kobayashi, R., & Beach, D. (1993) · Nature · doi:10.1038/366701a0 · Cited by 3,368
A short amino acid sequence able to specify nuclear location
Kalderon, D., Roberts, B. L., Richardson, W. D., & Smith, A. E. (1984) · Cell · doi:10.1016/0092-8674(84)90457-4 · Cited by 2,507
Polyak, K., Lee, M.-H., Erdjument-Bromage, H., Koff, A., Roberts, J. M., Tempst, P., & Massagué, J. (1994) · Cell · doi:10.1016/0092-8674(94)90572-x · Cited by 2,118
Self-citationp27, a novel inhibitor of G1 cyclin-Cdk protein kinase activity, is related to p21
Toyoshima, H., & Hunter, T. (1994) · Cell · doi:10.1016/0092-8674(94)90573-8 · Cited by 2,043
The p21 inhibitor of cyclin-dependent kinases controls DNA replication by interaction with PCNA
Waga, S., Hannon, G. J., Beach, D., & Stillman, B. (1994) · Nature · doi:10.1038/369574a0 · Cited by 1,655
Matsuoka, S., Edwards, M. C., Bai, C., Parker, S., Zhang, P., Baldini, A., Harper, J. W., & Elledge, S. J. (1995) · Genes & Development · doi:10.1101/gad.9.6.650 · Cited by 952
Matsushime, H., Ewen, M. E., Strom, D. K., Kato, J.-Y., Hanks, S. K., Roussel, M. F., & Sherr, C. J. (1992) · Cell · doi:10.1016/0092-8674(92)90360-o · Cited by 897
Lee, M. H., Reynisdóttir, I., & Massagué, J. (1995) · Genes & Development · doi:10.1101/gad.9.6.639 · Cited by 889
Self-citation
Research works printed but not linked: 1
- Kelman, Z., Naktinis, V. & O'Donnell, M. Meth. Enzym. (in the press).
Cited by
Inhibitors of mammalian G1 cyclin-dependent kinases.
Sherr, C. J., & Roberts, J. M. (1995) · Genes & Development · doi:10.1101/gad.9.10.1149 · Cited by 3,243
p21 in cancer: Intricate networks and multiple activities
Abbas, T., & Dutta, A. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2657 · Cited by 2,712
“The p21Waf1 pathway is involved in blocking leukemogenesis by the t(8;21) fusion protein AML1–ETO.”
BackgroundFero, M. L., Rivkin, M., Tasch, M., Porter, P., Carow, C. E., Firpo, E., Polyak, K., Tsai, L.-H., Broudy, V., Perlmutter, R. M., et al. (1996) · Cell · doi:10.1016/s0092-8674(00)81239-8 · Cited by 1,457
New functional activities for the p21 family of CDK inhibitors.
LaBaer, J., Garrett, M. D., Stevenson, L. F., Slingerland, J. M., Sandhu, C., Chou, H. S., Fattaey, A., & Harlow, E. (1997) · Genes & Development · doi:10.1101/gad.11.7.847 · Cited by 1,402
The Cell–Cycle Arrest and Apoptotic Functions of p53 in Tumor Initiation and Progression
Chen, J. (2016) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a026104 · Cited by 1,222
“p21 also interacts with proliferating cell nuclear antigen (PCNA) and inhibits DNA replication in vitro, which may contribute to its cell-cycle arrest activity (Luo et al. 1995).”
BackgroundEnhanced Growth of Mice Lacking the Cyclin-Dependent Kinase Inhibitor Function of p27
Kiyokawa, H., Kineman, R. D., Manova-Todorova, K. O., Soares, V. C., Hoffman, E. S., Ono, M., Khanam, D., Hayday, A. C., Frohman, L. A., & Koff, A. (1996) · Cell · doi:10.1016/s0092-8674(00)81238-6 · Cited by 1,251
CDK inhibitors: Cell cycle regulators and beyond
Besson, A., Dowdy, S. F., & Roberts, J. M. (2008) · Developmental Cell · doi:10.1016/j.devcel.2008.01.013 · Cited by 1,152
“…of cyclins and CDKs via the inhibition of components of the replication machinery. p21 was first reported to bind to proliferating cell nuclear antigen (PCNA), a DNA polymerase d processivity factor, via its C terminus (aa 143–160), thereby blocking processive DNA synthesis (Luo et al., 1995).”
Cheng, M., Olivier, P., Diehl, J. A., Fero, M., Roussel, M. F., Roberts, J. M., & Sherr, C. J. (1999) · The EMBO Journal · doi:10.1093/emboj/18.6.1571 · Cited by 1,142
“The Cip/Kip proteins interact with a variety of cyclin–CDK complexes through a conserved N-terminal domain that contains both cyclin and CDK binding sites (Toyoshima and Hunter, 1994; Chen et al., 1995, 1996; Luo et al., 1995; Nakanishi et al., 1995; Lin et al., 1996; Russo et al., 1996).”
BackgroundProliferating cell nuclear antigen (PCNA): a dancer with many partners
Maga, G., & Hübscher, U. (2003) · Journal of Cell Science · doi:10.1242/jcs.00653 · Cited by 1,096
“…-independent pathways induces the expression of the p21 protein, which blocks progression from G1 to S phase of the cell cycle. p21 binds to CDKs through its N-terminal region and to PCNA through its C-terminal region (Chen et al., 1995; Luo et al., 1995; Chen et al., 1996; Moskowitz et al., 1996).”
BackgroundCensus and evaluation of p53 target genes
Fischer, M. (2017) · Oncogene · doi:10.1038/onc.2016.502 · Cited by 971
Nagahara, H., Vocero-Akbani, A. M., Snyder, E. L., Ho, A., Latham, D. G., Lissy, N. A., Becker-Hapak, M., Ezhevsky, S. A., & Dowdy, S. F. (1998) · Nature Medicine · doi:10.1038/4042 · Cited by 928
The role of the cyclin-dependent kinase inhibitor p21 in apoptosis.
Gartel, A. L., & Tyner, A. L. (2002) · PubMed · Cited by 1,076
Cyclin E-CDK2 is a regulator of p27Kip1.
Sheaff, R. J., Groudine, M., Gordon, M., Roberts, J. M., & Clurman, B. E. (1997) · Genes & Development · doi:10.1101/gad.11.11.1464 · Cited by 911
Crystal structure of the p27Kip1 cyclin-dependent-kinase inibitor bound to the cyclin A–Cdk2 complex
Russo, A. A., Jeffrey, P. D., Patten, A. K., Massagué, J., & Pavletich, N. P. (1996) · Nature · doi:10.1038/382325a0 · Cited by 907
Self-citationLiu, M., Lee, M. H., Cohen, M., Bommakanti, M., & Freedman, L. P. (1996) · Genes & Development · doi:10.1101/gad.10.2.142 · Cited by 890
THE DNA REPLICATION FORK IN EUKARYOTIC CELLS
Waga, S., & Stillman, B. (1998) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.67.1.721 · Cited by 820
Structure of the C-Terminal Region of p21WAF1/CIP1 Complexed with Human PCNA
Gulbis, J. M., Kelman, Z., Hurwitz, J., O'Donnell, M., & Kuriyan, J. (1996) · Cell · doi:10.1016/s0092-8674(00)81347-1 · Cited by 804
Self-citationKip/Cip and Ink4 Cdk inhibitors cooperate to induce cell cycle arrest in response to TGF-beta.
Reynisdóttir, I., Polyak, K., Iavarone, A., & Massagué, J. (1995) · Genes & Development · doi:10.1101/gad.9.15.1831 · Cited by 962
Self-citationUncoupling of S phase and mitosis induced by anticancer agents in cells lacking p21
Waldman, T., Lengauer, C., Kinzler, K. W., & Vogelstein, B. (1996) · Nature · doi:10.1038/381713a0 · Cited by 728
Phosphorylation-dependent degradation of the cyclin-dependent kinase inhibitor p27Kip1
Vlach, J. (1997) · The EMBO Journal · doi:10.1093/emboj/16.17.5334 · Cited by 688
“Furthermore, FAR1 degrad- Ducommun, 1995; Lee et al., 1995; Luo et al., 1995; ation also depends upon phosphorylation by CDK1 Matsuoka et al., 1995; Nakanishi et al., 1995; Sherr and (S.Henchoz et al., submitted).”
BackgroundFunctional Analysis of Cyclin-Dependent Kinase Inhibitors of Arabidopsis
De Veylder, L., Beeckman, T., Beemster, G. T. S., Krols, L., Terras, F., Landrieu, I., Van Der Schueren, E., Maes, S., Naudts, M., & Inzé, D. (2001) · The Plant Cell · doi:10.1105/tpc.010087 · Cited by 640
“This result is consistent with the observation that a truncated form of p27Kip1 that lacks the 310 helix still retains inhibitory activity (Polyak et al., 1994; Luo et al., 1995).”
ResultStructural basis of cyclin-dependent kinase activation by phosphorylation
Russo, A. A., Jeffrey, P. D., & Pavletich, N. P. (1996) · Nature Structural & Molecular Biology · doi:10.1038/nsb0896-696 · Cited by 598
Apoptosis inhibitory activity of cytoplasmic p21Cip1/WAF1 in monocytic differentiation
Asada, M. (1999) · The EMBO Journal · doi:10.1093/emboj/18.5.1223 · Cited by 586
“The gene product also binds proliferating cell nuclear antigen (PCNA) through its C-terminal domain and blocks the ability of PCNA to activate DNA polymerase δ, the principal replicative DNA polymerase (Waga et al., 1994; Chen et al., 1995; Luo et al., 1995; Sherr and Roberts, 1995).”
BackgroundHeger, M., van Golen, R. F., Broekgaarden, M., & Michel, M. C. (2014) · Pharmacological Reviews · doi:10.1124/pr.110.004044 · Cited by 576
Kriwacki, R. W., Hengst, L., Tennant, L., Reed, S. I., & Wright, P. E. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.21.11504 · Cited by 575
High speed of fork progression induces DNA replication stress and genomic instability
Maya-Mendoza, A., Moudry, P., Merchut-Maya, J. M., Lee, M., Strauss, R., & Bartek, J. (2018) · Nature · doi:10.1038/s41586-018-0261-5 · Cited by 514
Otterbein, L. E., Zuckerbraun, B. S., Haga, M., Liu, F., Song, R., Usheva, A., Stachulak, C., Bodyak, N., Smith, R. N., Csizmadia, E., et al. (2003) · Nature Medicine · doi:10.1038/nm817 · Cited by 526
“5 ), and cell-cycle–dependent kinases (CDK) that regulate cell cycle progression through modulation of cyclin”
BackgroundEvaluation of the use of therapeutic peptides for cancer treatment
Marqus, S., Pirogova, E., & Piva, T. J. (2017) · Journal of Biomedical Science · doi:10.1186/s12929-017-0328-x · Cited by 512
“Chen et al. [19] observed that a p21 peptide fragment (139–164 AA) also bound to PCNA.”
BackgroundInfluentialFunk, J. O., Waga, S., Harry, J. B., Espling, E., Stillman, B., & Galloway, D. A. (1997) · Genes & Development · doi:10.1101/gad.11.16.2090 · Cited by 419
p21WAF1/Cip1: more than a break to the cell cycle?
Dotto, G. P. (2000) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/s0304-419x(00)00019-6 · Cited by 474
Levkau, B., Koyama, H., Raines, E. W., Clurman, B. E., Herren, B., Orth, K., Roberts, J. M., & Ross, R. (1998) · Molecular Cell · doi:10.1016/s1097-2765(00)80055-6 · Cited by 441
Multiple roles of the cell cycle inhibitor p21CDKN1A in the DNA damage response
Cazzalini, O., Scovassi, A. I., Savio, M., Stivala, L. A., & Prosperi, E. (2010) · Mutation Research/Reviews in Mutation Research · doi:10.1016/j.mrrev.2010.01.009 · Cited by 433
Cell-cycle inhibitors: three families united by a common cause
Vidal, A., & Koff, A. (2000) · Gene · doi:10.1016/s0378-1119(00)00092-5 · Cited by 431
Cdk inhibitors in development and cancer
Wade Harper, J., & Elledge, S. J. (1996) · Current Opinion in Genetics & Development · doi:10.1016/s0959-437x(96)90011-8 · Cited by 399
Strömblad, S., Becker, J. C., Yebra, M., Brooks, P. C., & Cheresh, D. A. (1996) · Journal of Clinical Investigation · doi:10.1172/jci118808 · Cited by 383
Pestell, R. G., Albanese, C., Reutens, A. T., Segall, J. E., Lee, R. J., & Arnold, A. (1999) · Endocrine Reviews · doi:10.1210/edrv.20.4.0373 · Cited by 375
Inhibition of p21‐mediated ROS accumulation can rescue p21‐induced senescence
Macip, S., Igarashi, M., Fang, L., Chen, A., Pan, Z., Lee, S. W., & Aaronson, S. A. (2002) · The EMBO Journal · doi:10.1093/emboj/21.9.2180 · Cited by 374
Adams, P. D., Sellers, W. R., Sharma, S. K., Wu, A. D., Nalin, C. M., & Kaelin, W. G. (1996) · Molecular and Cellular Biology · doi:10.1128/mcb.16.12.6623 · Cited by 373
“There are two such motifs within p21, one at the N terminus and one, unexpectedly in light of previously published data, at the C terminus (7, 18, 21, 43, 47, 54, 78).”
BackgroundInfluentialChang, M. W., Barr, E., Lu, M. M., Barton, K., & Leiden, J. M. (1995) · Journal of Clinical Investigation · doi:10.1172/jci118281 · Cited by 354
Reynisdóttir, I., & Massagué, J. (1997) · Genes & Development · doi:10.1101/gad.11.4.492 · Cited by 333
Self-citationPark, K.-R., Nam, D., Yun, H.-M., Lee, S.-G., Jang, H.-J., Sethi, G., Cho, S. K., & Ahn, K. S. (2011) · Cancer Letters · doi:10.1016/j.canlet.2011.08.001 · Cited by 331
“It negatively modulates cell cycle progression by inhibiting the activities of cyclin E/CDK2 and cyclin D/CDK4 complexes and blocks DNA replication by binding to proliferating cell nuclear antigen [32].”
BackgroundDacapo, a Cyclin-Dependent Kinase Inhibitor, Stops Cell Proliferation during Drosophila Development
Lane, M. E., Sauer, K., Wallace, K., Jan, Y. N., Lehner, C. F., & Vaessin, H. (1996) · Cell · doi:10.1016/s0092-8674(00)81818-8 · Cited by 327
Cyclin-Binding Motifs Are Essential for the Function of p21 CIP1
Chen, J., Saha, P., Kornbluth, S., Dynlacht, B. D., & Dutta, A. (1996) · Molecular and Cellular Biology · doi:10.1128/mcb.16.9.4673 · Cited by 320
“Second, as PCNA competes with cyclin-Cdk complexes for the C-terminal region (Cy2 site) of p21, the relative concentration of PCNA in crude extracts could determine whether p21 without a Cy1 site binds stably to cyclin E-Cdk2.”
BackgroundMethodInfluentialMissero, C., Di Cunto, F., Kiyokawa, H., Koff, A., & Dotto, G. P. (1996) · Genes & Development · doi:10.1101/gad.10.23.3065 · Cited by 312
PCNA: a silent housekeeper or a potential therapeutic target?
Wang, S.-C. (2014) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2014.02.004 · Cited by 285
p21WAF1 and tumourigenesis: 20 years after
Warfel, N. A., & El-Deiry, W. S. (2013) · Current Opinion in Oncology · doi:10.1097/cco.0b013e32835b639e · Cited by 286
“p21 can also influence the transcription of genes through direct binding and inhibition of PCNA, which inhibits DNA polymerase activity, transcription and excision repair functions [22].”
BackgroundCyclin dependent kinase regulation
Lees, E. (1995) · Current Opinion in Cell Biology · doi:10.1016/0955-0674(95)80060-3 · Cited by 285
Blain, S. W., Montalvo, E., & Massagué, J. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.41.25863 · Cited by 279
Self-citationCell cycle arrest and inhibition of anoikis by galectin-3 in human breast epithelial cells.
Kim, H.-R. C., Lin, H. M., Biliran, H., & Raz, A. (1999) · PubMed · Cited by 316
Expression of Cyclin-Dependent Kinase Inhibitors in Vascular Disease
Tanner, F. C., Yang, Z.-Y., Duckers, E., Gordon, D., Nabel, G. J., & Nabel, E. G. (1998) · Circulation Research · doi:10.1161/01.res.82.3.396 · Cited by 253
p107 uses a p21CIP1-related domain to bind cyclin/cdk2 and regulate interactions with E2F.
Zhu, L., Harlow, E., & Dynlacht, B. D. (1995) · Genes & Development · doi:10.1101/gad.9.14.1740 · Cited by 252
The Retinoblastoma Protein: A Master Regulator of Cell Cycle, Differentiation and Apoptosis
Herwig, S., & Strauss, M. (1997) · European Journal of Biochemistry · doi:10.1111/j.1432-1033.1997.t01-2-00581.x · Cited by 250
Role and Function of the 26S Proteasome in Proliferation and Apoptosis
Naujokat, C., & Hoffmann, S. (2002) · Laboratory Investigation · doi:10.1097/01.lab.0000022226.23741.37 · Cited by 247
“The CKI p21Cip1/WAF1 is proposed to negatively regulate G1- and early S-phase events through binding to CDKs and/or to proliferating cell nuclear antigen (PCNA) (Luo et al, 1995).”
A p53-independent Pathway for Activation of WAF1/CIP1 Expression Following Oxidative Stress
Russo, T., Zambrano, N., Esposito, F., Ammendola, R., Cimino, F., Fiscella, M., Jackman, J., O'Connor, P. M., Anderson, C. W., & Appella, E. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.49.29386 · Cited by 246
Gary, R., Ludwig, D. L., Cornelius, H. L., MacInnes, M. A., & Park, M. S. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.39.24522 · Cited by 238
Dutto, I., Tillhon, M., Cazzalini, O., Stivala, L. A., & Prosperi, E. (2015) · Archives of Toxicology · doi:10.1007/s00204-014-1430-4 · Cited by 236
Zhang, Y., Fujita, N., & Tsuruo, T. (1999) · Oncogene · doi:10.1038/sj.onc.1202426 · Cited by 237
“C-terminal residues 133 ± 164 were reported to act as the PCNA-binding region (Chen et al., 1995; Luo et al., 1995; Nakanishi et al., 1995a).”
BackgroundWu, H., Wade, M., Krall, L., Grisham, J., Xiong, Y., & Van Dyke, T. (1996) · Genes & Development · doi:10.1101/gad.10.3.245 · Cited by 234
Regulation of CDK/cyclin complexes during the cell cycle
Arellano, M., & Moreno, S. (1997) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/s1357-2725(96)00178-1 · Cited by 236
G1 and G2 cell-cycle arrest following microtubule depolymerization in human breast cancer cells
Blajeski, A. L., Phan, V. A., Kottke, T. J., & Kaufmann, S. H. (2002) · Journal of Clinical Investigation · doi:10.1172/jci13275 · Cited by 200
Suzuki, A., Ito, T., Kawano, H., Hayashida, M., Hayasaki, Y., Tsutomi, Y., Akahane, K., Nakano, T., Miura, M., & Shiraki, K. (2000) · Oncogene · doi:10.1038/sj.onc.1203429 · Cited by 232
“As a cell cycle regulator, p21 interacts with Cdk4 (Luo et al., 1995).”
BackgroundTranscriptional Activation of the p21 Gene by Interleukin-6 Type Cytokines
Bellido, T., O'Brien, C. A., Roberson, P. K., & Manolagas, S. C. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.33.21137 · Cited by 224
Cdk2 is dispensable for cell cycle inhibition and tumor suppression mediated by p27Kip1 and p21Cip1
Martín, A., Odajima, J., Hunt, S. L., Dubus, P., Ortega, S., Malumbres, M., & Barbacid, M. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.05.006 · Cited by 223
McAllister, S. S., Becker-Hapak, M., Pintucci, G., Pagano, M., & Dowdy, S. F. (2003) · Molecular and Cellular Biology · doi:10.1128/mcb.23.1.216-228.2003 · Cited by 212
“HepG2 cells were transduced with TATp27-KK protein containing a mutation in the cyclin binding domain (26), which fails to mediate G1 cell cycle arrest.”
Inhibitory effects of chitooligosaccharides on tumor growth and metastasis
Shen, K.-T., Chen, M.-H., Chan, H.-Y., Jeng, J.-H., & Wang, Y.-J. (2009) · Food and Chemical Toxicology · doi:10.1016/j.fct.2009.04.044 · Cited by 203
“It has also been reported that the inhibitory effect of p21 on DNA synthesis could be through the association of p21 and PCNA (Luo et al., 1995; Zhang et al., 1993).”
BackgroundAppleman, L. J., Berezovskaya, A., Grass, I., & Boussiotis, V. A. (2000) · The Journal of Immunology · doi:10.4049/jimmunol.164.1.144 · Cited by 203
WAF1 retards S-phase progression primarily by inhibition of cyclin-dependent kinases
Ogryzko, V. V., Wong, P., & Howard, B. H. (1997) · Molecular and Cellular Biology · doi:10.1128/mcb.17.8.4877 · Cited by 193
“The latter result is in agreement with earlier data (19); however, it must be stressed that the methodology used in that study did not allow one to discern which part of the cell cycle was affected, while the approach described here has been designed specifically to dissect the complex effects of CDKs and their inhibi…”
ResultMatsumura, I., Ishikawa, J., Nakajima, K., Oritani, K., Tomiyama, Y., Miyagawa, J.-I., Kato, T., Miyazaki, H., Matsuzawa, Y., & Kanakura, Y. (1997) · Molecular and Cellular Biology · doi:10.1128/mcb.17.5.2933 · Cited by 190
“The p21 protein is known to have two functional domains; one is the N-terminal domain that shows homology to the other Cdk inhibitors with a Cdk2-binding motif (aa 53 to 58), and the other is the C-terminal domain with a PCNA-binding motif(aa141to155)(5, 34 ,45).Thep21proteinbindsdirectly to a Cdk in complexes formed…”
BackgroundInfluentialArendt, T. (2003) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2003.09.007 · Cited by 188
p21/p53, Cellular Growth Control and Genomic Integrity
El-Deiry, W. S. (1998) · Current Topics in Microbiology and Immunology · doi:10.1007/978-3-642-71941-7_6 · Cited by 173
Poon, R. Y. C., Jiang, W., Toyoshima, H., & Hunter, T. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.22.13283 · Cited by 172
Kannaiyan, R., Manu, K. A., Chen, L., Li, F., Rajendran, P., Subramaniam, A., Lam, P., Kumar, A. P., & Sethi, G. (2011) · Apoptosis · doi:10.1007/s10495-011-0629-6 · Cited by 170
“They negatively modulate cell cycle progression by inhibiting the activity of cyclin/Cdk2 complexes and blocks DNA replication by binding to proliferating cell nuclear antigen [42].”
BackgroundStewart, Z. A., Leach, S. D., & Pietenpol, J. A. (1999) · Molecular and Cellular Biology · doi:10.1128/mcb.19.1.205 · Cited by 168
“In the cell, cyclin-Cdk-PCNA-p21 complexes are found throughout the cell cycle (29, 61‐63); p21 interacts with Cdks via its N terminus and with PCNA via its C terminus (3, 30 ).”
BackgroundRepression of p27 kip1 Synthesis by Platelet-Derived Growth Factor in BALB/c 3T3 Cells
Agrawal, D., Hauser, P., McPherson, F., Dong, F., Garcia, A., & Pledger, W. J. (1996) · Molecular and Cellular Biology · doi:10.1128/mcb.16.8.4327 · Cited by 168
“The carboxy-terminal region of p21 allows it to associate with proliferating cell nuclear antigen a processivity subunit of the DNA polymerase d holoenzyme (5, 19, 37, 49, 71).”
BackgroundMechanism Whereby Proliferating Cell Nuclear Antigen Stimulates Flap Endonuclease 1
Tom, S., Henricksen, L. A., & Bambara, R. A. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.275.14.10498 · Cited by 162
Ishida, A., Sasaguri, T., Kosaka, C., Nojima, H., & Ogata, J. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.15.10050 · Cited by 161
The UHRF family: Oncogenes that are drugable targets for cancer therapy in the near future?
Bronner, C., Achour, M., Arima, Y., Chataigneau, T., Saya, H., & Schini-Kerth, V. B. (2007) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2007.06.003 · Cited by 159
Biochemical and cellular mechanisms of mammalian CDK inhibitors: a few unresolved issues
Pei, X.-H., & Xiong, Y. (2005) · Oncogene · doi:10.1038/sj.onc.1208611 · Cited by 158
“The N-terminal region of p21, p27, and p57 contain an approximate 65 residue domain, consisting of two separable subdomains for binding to cyclin or CDK (Polyak et al., 1994b; Toyoshima and Hunter, 1994; Chen et al., 1995; Luo et al., 1995).”
BackgroundNguyen, H., Gitig, D. M., & Koff, A. (1999) · Molecular and Cellular Biology · doi:10.1128/mcb.19.2.1190 · Cited by 158
“These proteins were purified as described previously (36).”
MethodCytoplasmic p21Cip1/WAF1 regulates neurite remodeling by inhibiting Rho-kinase activity
Tanaka, H., Yamashita, T., Asada, M., Mizutani, S., Yoshikawa, H., & Tohyama, M. (2002) · The Journal of Cell Biology · doi:10.1083/jcb.200202071 · Cited by 166
“inhibits cyclin-Cdk kinases and a COOH-terminal domain of p21 Cip1/WAF1 inhibits proliferating cell nuclear antigen (Waga et al., 1994; Chen et al., 1995; Luo et al., 1995; Sherr and Roberts, 1995).”
BackgroundYan, G.-Z., & Ziff, E. B. (1997) · Journal of Neuroscience · doi:10.1523/jneurosci.17-16-06122.1997 · Cited by 171
“The p21 protein also inhibits the PCNA protein, an essential DNA replication protein (R. Li et al., 1994; Waga et al., 1994; Chen et al., 1995a; Luo et al., 1995).”
BackgroundWatanabe, H. A., Pan, Z., Schreiber‐Agus, N., DePinho, R. A., Hurwitz, J., & Xiong, Y. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.4.1392 · Cited by 175
Self-citationInhibitors of the Cip/Kip Family
Hengst, L., & Reed, S. I. (1998) · Current topics in microbiology and immunology · doi:10.1007/978-3-642-71941-7_2 · Cited by 188
Suzuki, A., Tsutomi, Y., Miura, M., & Akahane, K. (1999) · Oncogene · doi:10.1038/sj.onc.1202409 · Cited by 161
“The Cdk-binding domain in p21 was identi®ed as the 49 ± 71 amino acid region (Nakanishi et al., 1995) and the PCNA-binding domain is found in the 76 ± 164 amino acid region (Chen et al., 1995; Luo et al., 1995).”
BackgroundGorospe, M., Wang, X., Guyton, K. Z., & Holbrook, N. J. (1996) · Molecular and Cellular Biology · doi:10.1128/mcb.16.12.6654 · Cited by 154
Ball, K. L., Laín, S., Fåhræus, R., Smythe, C., & Lane, D. P. (1997) · Current Biology · doi:10.1016/s0960-9822(06)00029-7 · Cited by 157
Inhibition of nucleotide excision repair by the cyclin-dependent kinase inhibitor p21
Pan, Z.-Q., Reardon, J. T., Li, L., Flores-Rozas, H., Legerski, R., Sancar, A., & Hurwitz, J. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.37.22008 · Cited by 151
Self-citationKim, S., Lee, J. H., Sethi, G., Kim, C., Baek, S. H., Nam, D., Chung, W., Kim, S., Shim, B. S., & Ahn, K. S. (2014) · Cancer Letters · doi:10.1016/j.canlet.2014.08.002 · Cited by 154
p 21WAF1 C ontrol of E pithelial C ell C ycle and C ell F ate
Weinberg, W. C., & Denning, M. F. (2002) · Critical Reviews in Oral Biology & Medicine · doi:10.1177/154411130201300603 · Cited by 170
Coqueret, O., Bérubé, G., & Nepveu, A. (1998) · The EMBO Journal · doi:10.1093/emboj/17.16.4680 · Cited by 171
“E2F/Dp complexes function as transcriptional activators, however, association with a pocket protein during G0 and G1 appears to convert them to repressors (reviewed in Luo et al., 1995; Muller, 1995; Whyte, 1995).”
BackgroundStrategies for manipulating the p53 pathway in the treatment of human cancer
Hupp, T. R., Lane, D. P., & Ball, K. L. (2000) · Biochemical Journal · doi:10.1042/bj3520001 · Cited by 173
Shishodia, S., Sethi, G., Ahn, K. S., & Aggarwal, B. B. (2007) · Biochemical Pharmacology · doi:10.1016/j.bcp.2007.03.026 · Cited by 150
“They negatively modulate cell cycle progression by inhibiting the activity of cyclin/Cdk2 complexes and blocks DNA replication by binding to proliferating cell nuclear antigen [24].”
BackgroundArima, Y., Hirota, T., Bronner, C., Mousli, M., Fujiwara, T., Niwa, S., Ishikawa, H. T., & Saya, H. (2004) · Genes to Cells · doi:10.1111/j.1356-9597.2004.00710.x · Cited by 152
Subcellular distribution of p21 and PCNA in normal and repair-deficient cells following DNA damage
Li, R., Hannon, G. J., Beach, D., & Stillman, B. (1996) · Current Biology · doi:10.1016/s0960-9822(02)00452-9 · Cited by 161
“Recent studies have revealed that different domains of p21 interact with Cdks and PCNA, and that both of these domains can independently inhibit DNA replication when present in cells [35–38].”
Up-Regulation of MicroRNA-21 Correlates with Lower Kidney Cancer Survival
Zaman, M. S., Shahryari, V., Deng, G., Thamminana, S., Saini, S., Majid, S., Chang, I., Hirata, H., Ueno, K., Yamamura, S., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0031060 · Cited by 146
“In Western blot experiments we checked CDK4, E1 and E2 as CDK2 is already known to be affected by p21 gene [13,14].”
MethodA U-Rich Element in the 5′ Untranslated Region Is Necessary for the Translation of p27 mRNA
Millard, S. S., Vidal, A., Markus, M., & Koff, A. (2000) · Molecular and Cellular Biology · doi:10.1128/mcb.20.16.5947-5959.2000 · Cited by 135
“p27 PV3KK (32) was further mutated by site-directed mutagenesis using SSM51”
MethodHarris, T. E., Albrecht, J. H., Nakanishi, M., & Darlington, G. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m011587200 · Cited by 133
Suzuki, A., Tsutomi, Y., Yamamoto, N., Shibutani, T., & Akahane, K. (1999) · Molecular and Cellular Biology · doi:10.1128/mcb.19.5.3842 · Cited by 131
Roy, S., Kaur, M., Agarwal, C., Tecklenburg, M., Sclafani, R. A., & Agarwal, R. (2007) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-07-0104 · Cited by 131
“(41, 42), making its presence more crucial for observed silibinin effects.”
BackgroundPhosphorylation of p21 in G2/M Promotes Cyclin B-Cdc2 Kinase Activity
Dash, B. C., & El‐Deiry, W. S. (2005) · Molecular and Cellular Biology · doi:10.1128/mcb.25.8.3364-3387.2005 · Cited by 160
Metadata
- Authors
- Luo, Y., Hurwitz, J., & Massagué, J.
- Affiliations
- Memorial Sloan Kettering Cancer Center (US)
- ORCID
- Massagué, Joan
- Venue
- Nature
- Published
- 1995-05
- Volume
- 375
- Issue
- 6527
- Pages
- 159-161
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W2030231219
- Cited by
- 549
- References
- 18
- Citations by year
- 2026: 2 · 2025: 3 · 2024: 3 · 2023: 3 · 2022: 7 · 2021: 11 · 2020: 11 · 2019: 6 · 2018: 8 · 2017: 13 · 2016: 12 · 2015: 9 · 2014: 8 · 2013: 7 · 2012: 16
- FWCI
- 23.57
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › DNA Repair Mechanisms
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Microtubule and mitosis dynamics
- Keywords
- p21, cyclin-dependent kinases, proliferating cell nuclear antigen, C-terminal domain, cell cycle inhibition, DNA replication inhibition, p27, p57KIP2, S phase entry
- MeSH terms
- Amino Acid Sequence, Animals, Binding Sites, Cell Cycle, DNA, Humans, Molecular Sequence Data, Recombinant Fusion Proteins, Cyclins, Protein Serine-Threonine Kinases, Proliferating Cell Nuclear Antigen, Cyclin-Dependent Kinases, CDC2-CDC28 Kinases, Cyclin-Dependent Kinase Inhibitor p21, Cyclin-Dependent Kinase 2, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.